Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.37 Billion CNY
Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has total liabilities worth CN¥2.37 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Lianhuan Pharmaceutical Co Ltd - Total Liabilities Trend (2000–2024)
This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CH. Karnchang PCL
BK:CK
|
Thailand | ฿87.98 Billion |
|
Rocket Internet SE
HM:RKET
|
Germany | €243.60 Million |
|
Matas A/S
CO:MATAS
|
Denmark | Dkr5.90 Billion |
|
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
|
China | CN¥1.22 Billion |
|
Rayonier Advanced Materials
NYSE:RYAM
|
USA | $1.44 Billion |
|
Shanghai Anoky Group
SHE:300067
|
China | CN¥1.03 Billion |
|
Shanghai Hugong Elec(Group)
SHG:603131
|
China | CN¥870.11 Million |
|
Ingram Micro Holding Corporation
NYSE:INGM
|
USA | $17.00 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Jiangsu Lianhuan Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Lianhuan Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)
The table below shows the annual total liabilities of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.44 Billion | +7.76% |
| 2023-12-31 | CN¥1.34 Billion | +2.86% |
| 2022-12-31 | CN¥1.30 Billion | +21.17% |
| 2021-12-31 | CN¥1.07 Billion | +23.85% |
| 2020-12-31 | CN¥867.05 Million | +7.63% |
| 2019-12-31 | CN¥805.57 Million | +70.16% |
| 2018-12-31 | CN¥473.43 Million | +65.39% |
| 2017-12-31 | CN¥286.25 Million | +19.75% |
| 2016-12-31 | CN¥239.03 Million | +5.92% |
| 2015-12-31 | CN¥225.66 Million | +0.43% |
| 2014-12-31 | CN¥224.71 Million | -9.16% |
| 2013-12-31 | CN¥247.36 Million | +166.59% |
| 2012-12-31 | CN¥92.79 Million | +2.07% |
| 2011-12-31 | CN¥90.91 Million | -1.33% |
| 2010-12-31 | CN¥92.13 Million | +2.97% |
| 2009-12-31 | CN¥89.47 Million | +14.74% |
| 2008-12-31 | CN¥77.98 Million | -11.07% |
| 2007-12-31 | CN¥87.69 Million | +14.41% |
| 2006-12-31 | CN¥76.64 Million | +55.03% |
| 2005-12-31 | CN¥49.44 Million | -19.79% |
| 2004-12-31 | CN¥61.63 Million | +31.16% |
| 2003-12-31 | CN¥46.99 Million | +14.56% |
| 2002-12-31 | CN¥41.02 Million | -11.17% |
| 2001-12-31 | CN¥46.18 Million | -4.80% |
| 2000-12-31 | CN¥48.51 Million | -- |